Moderna’s coronavirus vaccine enters phase-II clinical trial

0
0

After receiving encouraging results in its phase-I clinical trial, the US biotech company Moderna has announced that its COVID-19 vaccine has entered phase two, adding that 600 volunteers have been administered the vaccine. In a statement, Moderna said that the participants will receive two vaccinations 28 days apart of a placebo, a 50-microgram dose or a-100 microgram dose.

NO COMMENTS